Heart scans could uncover silent damage in liver patients awaiting transplant

NCT ID NCT06327308

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This pilot study is testing whether cardiac MRI can detect and track heart muscle scarring in people with cirrhosis who are waiting for a liver transplant. Researchers want to see if inflammation from the liver disease affects the heart, and whether a transplant can reverse that damage. Sixty participants will undergo MRI scans before and after their transplant to monitor changes in the heart muscle.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cardiac MRI
What this could lead to
If successful, this could help doctors detect and monitor heart problems in people with cirrhosis, potentially improving care before and after liver transplant.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. MRI scans can be uncomfortable and may not be suitable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion of cirrhotic patients who are candidates for liver transplantation and without documented contraindications to transplantation * Women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing age, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) * Signature of an informed consent form indicating that the subject has understood the purpose and procedures required by the study and that he or she agrees to participate in the study and to comply with the requirements and restrictions inherent in the study * Patient with a social security system or beneficiary of such a system. Exclusion Criteria: * Minor or over 70 years old * Transplant Patient * Patient with a TIPS * Known heart disease including portopulmonary hypertension and coronary artery disease (history of ischemic heart disease with necrosis, history of cardiomyopathy or acute myocarditis) * Uncontrolled hypertension with interventricular septal thickness ≥ 15 mm * Hemodynamic instability * Type 1 diabetes * Current bacterial infection * HIV infection (or unknown HIV status) * Contraindications for MRI including pacemaker, implantable defibrillators, electrosystolic pacing probe, Swan-Ganz probe, postoperative epicardial electrodes, Starr-Ewards metal ball valves, insulin pumps, ferromagnetic vascular clips, ocular and otological implants, ocular ferromagnetic foreign bodies, renal failure with a GFR \< 30 mL/min/1.73 m², contraindication to contrast media, patient unable to maintain apnea for a few seconds, claustrophobia * Inability to receive informed information in patients with severe encephalopathy who do not have a trusted person * Patient under guardianship, curatorship, Legal incapacity or limited legal capacity * Patient deprived of liberty * Pregnant woman or breastfeeding * Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator * Subject being in the period of exclusion from another study or provided for by the "national volunteer file"

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Nancy - Hôpital de Brabois

    RECRUITING

    Nancy, 54000, France

  • CHU Besancon - Hopital Minjoz

    RECRUITING

    Besançon, 25000, France

  • CHU Dijon - Hopital François Mitterrand

    RECRUITING

    Dijon, 21000, France

  • CHU Strasbourg - Hopital de HautePierre

    NOT_YET_RECRUITING

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.